St. Jude Children’s Research Hospital, University of Pavia, Dana-Farber Cancer Institute and Harvard Medical School unveiled AdaptiveFlow, an AI-informed platform claimed to virtually screen billions of drug-like molecules with around a 1,000-fold reduction in computational costs versus existing methods. The system was validated and published in Nature Biotechnology. The approach is positioned as an answer to the economics of ultra-large virtual screening—turning what is typically prohibitive compute into a workflow that teams can run routinely. If the claimed cost compression holds up across targets, it could accelerate hit discovery cycles and reduce time-to-signal in early-stage programs. For biotech development teams, the central question will be reproducibility across different protein targets and whether downstream hit triage improves clinical translation versus existing screening pipelines.